share_log

T2 Biosystems | S-1: General form for registration of securities under the Securities Act of 1933

T2 Biosystems | S-1: General form for registration of securities under the Securities Act of 1933

T2 Biosystems | S-1：證券上市註冊聲明
美股sec公告 ·  04/23 05:17
牛牛AI助理已提取核心訊息
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on April 22, 2024, for a Registration Statement under the Securities Act of 1933. This filing indicates T2 Biosystems' intent to offer shares of common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock. The offering is to commence as soon as practicable after the Registration Statement is declared effective. T2 Biosystems, based in Lexington, Massachusetts, is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol 'TTOO.' The company has engaged a placement agent to use reasonable best efforts to solicit offers to purchase the securities. The offering...Show More
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on April 22, 2024, for a Registration Statement under the Securities Act of 1933. This filing indicates T2 Biosystems' intent to offer shares of common stock, pre-funded warrants to purchase common stock, and common warrants to purchase common stock. The offering is to commence as soon as practicable after the Registration Statement is declared effective. T2 Biosystems, based in Lexington, Massachusetts, is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol 'TTOO.' The company has engaged a placement agent to use reasonable best efforts to solicit offers to purchase the securities. The offering includes provisions for the sale of pre-funded warrants to investors who would otherwise exceed beneficial ownership limits. The proceeds from the offering are intended for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs. The offering is expected to close no later than 2024, subject to customary closing conditions.
T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年4月22日向美國證券交易委員會（SEC）提交了S-1表格，要求根據1933年《證券法》提交註冊聲明。該文件表明，T2 Biosystems打算髮行普通股、購買普通股的預先資金認股權證和購買普通股的普通認股權證。此次發行將在註冊聲明宣佈生效後儘快開始。總部位於馬薩諸塞州列剋星敦的T2 Biosystems在特拉華州註冊成立，在納斯達克資本市場上交易，股票代碼爲 “TTOO”。該公司已聘請配售代理人盡最大努力征求購買證券的要約。此次發行包括向否則將超過實益所有權限的投資者出售預先注資的認股權證的條款。此次發行的收益將用於營運資金和一般公司用途，包括銷售和營銷、製造和臨床開發成本。此次發行預計不遲於2024年結束，但須遵守慣例成交條件。
T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年4月22日向美國證券交易委員會（SEC）提交了S-1表格，要求根據1933年《證券法》提交註冊聲明。該文件表明，T2 Biosystems打算髮行普通股、購買普通股的預先資金認股權證和購買普通股的普通認股權證。此次發行將在註冊聲明宣佈生效後儘快開始。總部位於馬薩諸塞州列剋星敦的T2 Biosystems在特拉華州註冊成立，在納斯達克資本市場上交易，股票代碼爲 “TTOO”。該公司已聘請配售代理人盡最大努力征求購買證券的要約。此次發行包括向否則將超過實益所有權限的投資者出售預先注資的認股權證的條款。此次發行的收益將用於營運資金和一般公司用途，包括銷售和營銷、製造和臨床開發成本。此次發行預計不遲於2024年結束，但須遵守慣例成交條件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。